



S-1539

Bone Forming Peptide-2 (BFP-2) (human) ELISA

Bone Forming Peptide-2 (BFP-2) is a peptide derived from the immature region of the Bone Morphogenetic Proteins-7 (BMP-7). It is known to enhance osteogenic differentiation of multipotent bone marrow stromal stem cells (BMSCs) and upregulate biological markers of osteogenesis. First studies suggest that BFP-2 may be used as an osteogenic stimulator instead of BMP-7 in future clinical trials of bone generation engineering.

This ELISA was developed with serum from rabbits immunized with Bone Forming Peptide-2 coupled to a carrier protein.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Lot number: n/a

Host species: Rabbit IgG

Quantity: 96 tests

Format: Formulated for extracted samples (EIAH type).

Shelf-life: One year from production date. Store refrigerated at 4° - 8°C.

Applications: This ELISA has been validated with the included reagents. It is intended

to be used with appropriately extracted samples (original protocol III,

Std.Ab1hr.Bt). For research use only.

Please see www.bma.ch for protocols and general information.

Range: 0-100ng/ml Average IC50: 6ng/ml


Immunogen: Synthetic peptide H-Val-Glu-His-Asp-Lys-Glu-Phe-Phe-His-Pro-Arg-Tyr-

His-His-OH coupled to carrier protein.

Cross-Reactivity:

PEPTIDE: %:
Bone Forming Peptide-2 (BFP-2) (human) 100
Bone-Forming Peptide-1 (BFP-1) (human) 0

Typical titration curve of Bone Forming Peptide-2 in a competitive ELISA with this antibody:



Suggested Preparation of Standards			
	ng/ml	Range: 0.10 to 100ng/ml	
Stock	1000		
S1	100.00	Add 100µl Stock	+ 900µl diluent
S2	25.00	Add 200µl S1	+ 600µl diluent
S3	6.25	Add 200µl S2	+ 600µl diluent
S4	1.56	Add 200µl S3	+ 600µl diluent
S5	0.39	Add 200µl S4	+ 600µl diluent
S6	0.10	Add 200µl S5	+ 600µl diluent
S0	0.00		500µl diluent

Related Products: S-1538: Bone Forming Peptide-1, ELISA (hu)

This product contains Thimerosal as a preservative and is intended for laboratory use and research purposes only. Purchase of this product does not include authorization to use it in diagnostic or therapeutic applications.

S-1539 EIAH 1.03.2021